<DOC>
	<DOCNO>NCT00873210</DOCNO>
	<brief_summary>Objective study increase knowledge safety , tolerability , quality life efficacy condition routine use sunitinib .</brief_summary>
	<brief_title>Study In Patients With Kidney Cancer Treated With Sutent</brief_title>
	<detailed_description>Consecutive patient advance metastatic renal cell carcinoma , indicate 1st 2nd line anticancer therapy</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Consecutive patient advance metastatic renal cell carcinoma , indicate 1st 2nd line anticancer therapy Hypersensitivity sunitinib malate excipients Any contraindication use sunitinib malate ( base decision treat physician ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>sunitinib malate</keyword>
</DOC>